GSK Stock Price and Chart — NYSE:GSK

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

Key facts today

A U.S. probe into drug imports, starting April 1, may impact GSK's Q1 results. Barclays analysts highlight GSK's significant exposure to potential tariff risks from this investigation.

GSK breached ethical standards in marketing its drug Omjjara, misleading women on contraceptive precautions. The PMCPA has ruled on this issue, but GSK has not commented.

On April 15, 2025, GSK plc acquired 28,311,101 shares in its buyback program, increasing treasury shares to 197,381,404. Total issued shares, excluding treasury, is 4,117,853,751.

Analyze the impact Analyze the impact

About GSK PLC ORD GBP0.3125

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.